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the ester oxygen replaced by a methylene group and are
thus not susceptible to nucleophilic attack by the active
site cysteine. Some of these compounds (such as 14, 17,
and 18; see Scheme 3 of Wu et al. [1]) are competitive in-
hibitors with Ki values in the lower micromolar range and
are thus among the most potent noncovalent inhibitors
of the SARS-CoV Mpro described to date. The discovery
of compounds binding noncovalently to the Mpro may, in
the end, constitute a more important milestone on the
way to clinically useful inhibitors of the coronavirus main
proteinase than identification of the acylating agents.
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Figure 1. Chemical formulas of (A) AG7088, (B-D) AG7088 deriva-
tives, (E) lopinavir, (F) 1-(benzoyloxy)-benzotriazole (R=4-NHCH3,
4-N(CH3)2, or 4-N(C2H5)2).
Chemistry & Biology
236Pharmacogenetics:
Yeast Lead the Way
In this issue of Chemistry & Biology, Perlstein et al. [1]
use genetically diverse strains of yeast to study the
genetic basis of differences in cellular responses tosmall molecules. Their results suggest that drug re-
sponses are regulated by a limited number of loci,
and that this system can identify clusters of function-
ally similar molecules.
When given a standard dose of commonly prescribed
drugs, a significant fraction of patients will either receive
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237no therapeutic benefit or will experience an undesired
side effect. Pharmacogenetics is the study of the ge-
netic basis of variation in responses to drugs, which is
thought to account for a large fraction of differences in
drug responses among human populations [2]. Perlstein
et al. explore the issue of how genetic differences affect
drug response in outbred yeast strains, and they do so
with a level of experimental rigor impossible in other sys-
tems [1].
To initiate this study, two yeast strains were used:
a standard laboratory strain and a strain isolated
from an AIDS patient [3]. The entire genome of both
strains has been sequenced. The two strains exhibit
1022 changes per synonymous site, a level of genetic
divergence comparable to that between humans and
chimps [4]. The authors first identified 23 small mole-
cule perturbagens (SMPs) that were differentially toxic
to three different diploid strains of yeast: the homo-
zygous laboratory strain, the homozygous clinical iso-
late, and a heterozygote between the two strains. The
SMPs, split roughly equally between natural products
and synthetic chemicals, include seven FDA-approved
drugs. Differential toxicity among these strains ensured
that there would be interesting pharmacogenetic dif-
ferences between the progeny of the heterozygous
diploid.
The authors sporulated the heterozygous diploid to
generate a genetically diverse population of 2246 hap-
loid progeny, each of whose genomes contained a
unique combination of alleles inherited from the clinical
strain and the laboratory strain. A sensitivity profile to
the 23 SMPs was determined for each haploid strain
by measuring the degree to which each compound in-
hibited growth.
To begin to address the issue of pharmacogenetic
complexity, the authors estimated the number of genetic
loci that control sensitivity to each of the 23 SMPs. The
distribution of sensitivities to a certain drug across all
progeny is expected to reflect the number of loci that in-
fluence sensitivity to that drug. For example, if half of the
segregants are resistant to a certain SMP and half are
sensitive, it is likely that a single locus controls sensitiv-
ity, whereas if three quarters are resistant and one quar-
ter are sensitive, it is more likely that two loci control
sensitivity. Assuming that the fraction of resistant segre-
gants approximates (1/2)n, the authors determined that
sensitivity to all SMPs was controlled by no more than
four loci, and only one SMP, flunarizine, was controlled
by only a single locus. Interestingly, there was a kinetic
component to resistance. For example, although sensi-
tivity to flunarizine appeared to be controlled by only
one locus when growth inhibition was measured at
48 hr, it appeared to be controlled by two loci 24 hr later.
This kinetic component was seen with several SMPs,
emphasizing the pharmacogenetic complexity in the
population.
The fact that the numbers of genetic determinants
appeared to vary from one to four across the 23 SMPs
was consistent with the idea that they reflected a large
number of genetic differences that affected sensitivity
to a small number of drugs rather than the converse.
The pattern of sensitivity to different SMPs among the
segregants, analyzed by two-dimensional hierarchical
clustering demonstrated that the genetic determinantscontrolling sensitivity to most SMPs segregated inde-
pendently of each other.
Although the majority of SMPs elicited unrelated pat-
terns of sensitivity, principal component analysis (PCA)
identified clusters of SMPs that elicited similar patterns.
PCA is a method of dimensionality reduction that places
the SMP in three dimensional ‘‘chemical space’’ accord-
ing to the pattern of segregant sensitivity, and can there-
fore be used to measure the relatedness between differ-
ent SMPs and group them into clusters. Prior knowledge
of the biological effects of the SMPs in three of these
clusters confirmed that this mathematical clustering was
biologically meaningful. One cluster consisted of five
molecules that, although structurally unrelated, all mod-
ulate calcium ion homeostasis. A second cluster con-
sisted of four molecules known or postulated to modu-
late respiratory metabolism. A third cluster consisted
of two molecules that, although structurally different,
both inhibit calmodulin, a master regulator of calcium-
mediated signaling. These results suggest that principle
component analysis of the patterns of sensitivity elicited
in genetically diverse populations of yeast could prove
a powerful tool for identifying compounds whose bio-
logical effects are similar to those of known compounds
but whose structure, and perhaps mechanism of action,
are unrelated.
Analysis of the patterns of sensitivity elicited by these
SMPs proved valuable not only for identifying molecules
with similar biological activities, but also for identify-
ing interactions between molecules and the biological
processes on which they impinge. For example, princi-
ple component analysis demonstrated that two SMPs
that modulate calcium homeostasis reside at the
opposite corners of PCA-defined chemical space from
three SMPs that modulate respiration. This relationship
is manifested in an underrepresentation of segregants
that are resistant to both the modulators of calcium
homeostasis and the modulators of respiration, and it
suggests an interaction between the two biological pro-
cesses. This hypothesis was further strengthened by
treating segregants that were resistant to SMPs from
both classes with a combination of one SMP from each
class; although these strains were not sensitive to either
class of SMPs, the combination of one from each class
completely inhibited growth. This result suggests that
patterns of sensitivity elicited in genetically diverse pop-
ulations of yeast could prove a powerful tool for identify-
ing toxic interactions between drugs.
Finally, the authors demonstrated that their approach
was, in fact, identifying genetic loci that regulate drug
responses by mapping some of the loci responsible for
modulating drug responses. To accomplish this, they
turned to a cross between the laboratory strain and
densely genotyped agricultural isolate [5] whose ge-
nome is comparably divergent from the laboratory strain
as is the clinical isolate.
The observation that most responses to drugs were
controlled by four or fewer genes combined with the
fact that the authors were able to map loci that con-
trolled these responses is encouraging for the prospects
of progress in pharmacogenetic studies in humans. The
CEPH cell lines (http://www.cephb.fr/) are a promising
resource for initiating a comparable study in human
cells. These densely genotyped cell lines were collected
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238from large Mormon families whose lineages and histo-
ries of disease are well documented and have been
used successfully for mapping several quantitative traits
such as gene transcript levels [6]. Furthermore, the
single nucleotide polymorphisms represented in this
collection, including those in genes that participate in
drug metabolism [7], are commonly found in the rest of
population. Systematic identification of the alleles that
control drug responses in humans will be an important
step toward individualized drug therapy.
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